An Intra-Cellular Therapies Inc. patent describes new 5-HT2A, μ-opioid, and dopamine D1 and D2 receptor ligands reported to be useful for the treatment of neurological disorders.
Heng Liu, R. N. V. Krishna Deepak, Anna Shiriaeva, Cornelius Gati, Alexander Batyuk, Hao Hu, Uwe Weierstall, Wei Liu, Lei Wang, Vadim Cherezov, Hao Fan, Cheng Zhang Proceedings of the National Academy ...
The dopamine D2 receptor (D2R) is a validated target for the treatment of neuropsychiatric disorders. Many antipsychotics, however, do not just target the D2R, which explains the number of side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback